{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Medicine&page=2",
    "query": {
      "condition": "Pulmonary Medicine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Medicine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T07:31:51.380Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05579366",
      "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Epithelial Ovarian Cancer",
        "High Grade Serous Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Non-small Cell Lung Cancer",
        "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)",
        "Mesothelioma",
        "Breast Adenocarcinoma",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive/Her2 Negative Breast Cancer",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Platinum Sensitive Ovarian Cancer (PSOC)",
        "Primary Refractory Ovarian Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 884,
      "start_date": "2022-12-07",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05579366"
    },
    {
      "nct_id": "NCT00079794",
      "title": "Iscar for Supplemental Care in Stage IV Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Iscar",
          "type": "DRUG"
        },
        {
          "name": "mistletoe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2001-09",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2008-01-25",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079794"
    },
    {
      "nct_id": "NCT04826341",
      "title": "A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HRD Cancer",
        "SCLC",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 35,
      "start_date": "2021-09-20",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04826341"
    },
    {
      "nct_id": "NCT00224042",
      "title": "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia, Iron-Deficiency",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "Sodium Ferric Gluconate complex in sucrose",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2012-03-29",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224042"
    },
    {
      "nct_id": "NCT00000796",
      "title": "A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Ethionamide",
          "type": "DRUG"
        },
        {
          "name": "Capreomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Aminosalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "Streptomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Amikacin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Clofazimine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 525,
      "start_date": null,
      "completion_date": "1998-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 21,
      "location_summary": "Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000796"
    },
    {
      "nct_id": "NCT02197247",
      "title": "Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic sampling - AZD9291",
          "type": "PROCEDURE"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        },
        {
          "name": "AZD9291 tablet dosing",
          "type": "DRUG"
        },
        {
          "name": "Pharmacokinetic sampling - rifampicin",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacokinetic sampling - AZ5140 and AZ7550",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 41,
      "start_date": "2014-12-04",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Detroit, Michigan",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197247"
    },
    {
      "nct_id": "NCT00003089",
      "title": "Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-07",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003089"
    },
    {
      "nct_id": "NCT04250779",
      "title": "Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Adherence, Medication",
        "Childhood Asthma"
      ],
      "interventions": [
        {
          "name": "CapMedic smart inhaler device",
          "type": "DEVICE"
        },
        {
          "name": "Video-based guidance",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Landon Pediatric Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-07-01",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04250779"
    },
    {
      "nct_id": "NCT02808689",
      "title": "Functional Medicine in Asthma (FAst) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Lifestyle Factors",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Customized use of Dietary Supplements",
          "type": "OTHER"
        },
        {
          "name": "Currently Accepted Asthma Care Guidelines",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-09",
      "completion_date": "2021-02",
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808689"
    },
    {
      "nct_id": "NCT03014674",
      "title": "A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Lyophilized mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Liquid mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prefilled autoinjector",
          "type": "DEVICE"
        },
        {
          "name": "Prefilled Safety Syringe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 246,
      "start_date": "2017-01-06",
      "completion_date": "2017-08-11",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-07-23T07:31:51.380Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014674"
    }
  ]
}